Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
Go back to Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder| (NASDAQ: VTGN) | Delayed: 0.64 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.64 | 52 Week High | $4.60 | |||
| Open | $0.64 | 52 Week Low | $2.81 | |||
| Day High | $0.64 | P/E | N/A | |||
| Day Low | $0.64 | EPS | $0.00 | |||
| Volume | 15,716 | |||||
